Muhammad Ahmed, MD
Endocrinology, Diabetes & Metabolism · Fairbanks, AKNPI 1457316051
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $973 of the $1,316 with a category attached, or 73.9%. 14 manufacturers reported payments, led by Edwards Lifesciences at 31.3% of the total. Reporting peaked in 2019 at $620 and has fallen 81.8% since, to $113 in 2025.
Across 26 payments — averaging $50.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$412
- Medtronic$228
- Amgen$125
- Novo Nordisk$123
- Tandem Diabetes Care, Inc.$123
- Lilly USA, LLC$69
- plus $236 from 8 others
What the payments were for
- Travel & lodging$34326%
- Food & beverage$97374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 2 | $412 |
| Medtronic(2 entities) | 7 | $228 |
| Amgen | 1 | $125 |
| Novo Nordisk | 3 | $123 |
| Tandem Diabetes Care, Inc. | 3 | $123 |
| Lilly USA, LLC | 2 | $69 |
| Abbott | 1 | $61 |
| BETA Bionics, Inc. | 1 | $61 |
| AbbVie | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| Mannkind Corporation | 1 | $19 |
| Cequr Corporation | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Insulet Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$125
How this compares
Too few endocrinology, diabetes & metabolism providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 133 | $194,641 |
| Teriparatide | 72 | $179,213 |
| ForteoTeriparatide | 22 | $92,315 |
| MounjaroTirzepatide | 50 | $62,361 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 15 | $37,334 |
| ProliaDenosumab | 22 | $37,127 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $28,738 |
| JardianceEmpagliflozin | 15 | $24,052 |
| FarxigaDapagliflozin Propanediol | 16 | $18,193 |
| TrulicityDulaglutide | 19 | $17,577 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,646 |
| JanuviaSitagliptin Phosphate | 15 | $12,073 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $9,561 |
| Cinacalcet Hcl | 38 | $9,029 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $7,359 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $123 | $199,883156 claims |
| Lilly USA, LLCForteo, Mounjaro, Trulicity | $69 | $172,25291 claims |
| AmgenProlia | $125 | $37,12722 claims |
| AbbVieSynthroid | $23 | $2,23728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Fairbanks
- Jerry TannerAnchorage$18K
- Jeffrey MedlandAnchorage$9K
- Janice KovalAnchorage$6K
- Samuel AbbateWasilla$2K
- Jeanne BonarAnchorage$2K
- Konrad KaltenbornAnchorage$1K
- Patrick NolanAnchorage$986
- Laily MahooziCordova$83
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.